These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21211076)

  • 1. [Treat haematology patients as long as possible].
    Huijgens PC
    Ned Tijdschr Geneeskd; 2010; 154(51-52):A2882. PubMed ID: 21211076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive care for patients with medical complications of haematological malignancy: is it worth it?
    Hinds CJ; Martin R; Quinton P
    Schweiz Med Wochenschr; 1998 Sep; 128(39):1467-73. PubMed ID: 9793166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness, chemotherapy, and the clinician.
    Griggs JJ; Sorbero ME
    Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care].
    Zambrowski JJ
    Bull Cancer; 2008 May; 95(5):535-41. PubMed ID: 18541518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of chemotherapy in the treatment of colorectal cancer.
    Jansman FG; Postma MJ
    Eur J Health Econ; 2006 Jun; 7(2):145-6. PubMed ID: 16699776
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic and cost-effectiveness issues in breast cancer treatment.
    Hillner BE
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs for treatment of disseminated breast cancer.
    Dahlberg L; Lundkvist J; Lindman H
    Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning regimens in malignant haematological diseases.
    Buffart TE; Janssen JJ; Huijgens PC
    Neth J Med; 2005 Feb; 63(2):43-51. PubMed ID: 15766008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Palliative care with respect to demographic change. How much can society afford?].
    Schmacke N
    Med Klin (Munich); 2007 Jul; 102(7):582-5. PubMed ID: 17634877
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation.
    Sahlstedt L; von Bonsdorff L; Ebeling F; Parkkinen J; Juvonen E; Ruutu T
    Eur J Haematol; 2009 Nov; 83(5):455-9. PubMed ID: 19572995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis.
    Nieboer P; de Vries EG; Vellenga E; van der Graaf WT; Mulder NH; Sluiter WJ; de Wolf JT
    Eur J Cancer; 2004 May; 40(8):1199-207. PubMed ID: 15110884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of cure.
    Schmiegelow K; Frandsen TL
    Lancet Haematol; 2018 Nov; 5(11):e504-e505. PubMed ID: 29907548
    [No Abstract]   [Full Text] [Related]  

  • 16. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
    Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
    Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study on home care for patients with hematologic malignancies.
    Kodama Y; Takita M; Kawagoe S; Hirahara S; Kimura Y; Onozawa S; Wada T; Nakano K; Kami M; Matsumura T; Yuji K
    Jpn J Clin Oncol; 2009 Sep; 39(9):606-11. PubMed ID: 19535385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting.
    Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
    Intern Med J; 2009 Aug; 39(8):519-26. PubMed ID: 19732200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Key ethic discussions in hospice/palliative care].
    Jusić A
    Acta Med Croatica; 2008 Dec; 62(5):447-54. PubMed ID: 19382626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late infectious complications after high-dose therapy and autologous blood stem cell transplantation].
    Metzner B; Grüneisl R; Gebauer W; Reschke D; Ost E; Müller TH; Reichert D; Rosien B; Del Valle F; Zirpel I; Kohse KP; Schunter F; Illiger HJ
    Med Klin (Munich); 2002 Nov; 97(11):650-8. PubMed ID: 12434273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.